Prevalence of KRAS and Concomitant Mutations in Advanced Lung Adenocarcinoma Patients

被引：0
|
作者：
Gil Ferreira, C. [1 ]
Montella, T. [1 ]
Moreira De Sousa, C. [2 ]
Zalis, M. [3 ]
Aran, V. [4 ]
机构：
[1] Oncoclinicas, Rio De Janeiro, Brazil
[2] Univ Estado Rio Janeiro Uerj, Fac Ciencias Med Fcm, Dept Tecnol Informacao & Educ Saude Dties, Rio De Janeiro, Brazil
[3] Oncoclinicas, Sao Paulo, Brazil
[4] Inst Estadual Cerebro Paulo Niemeyer, Rio De Janeiro, Brazil
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
advanced lung adenocarcinoma; concomitant mutations; KRAS;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P70.10
引用
收藏
页码：S1214 / S1214
页数：1
相关论文
共 50 条
  • [41] Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma
    Riely, G. J.
    Kris, M. G.
    Marks, J. L.
    Li, A.
    Chitale, A.
    Riedel, E. R.
    Hsu, M.
    Pao, W.
    Miller, V. A.
    Ladanyi, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [42] Clinical Impact of EGFR vs KRAS Mutations in Multifocal Lung Adenocarcinoma
    Jiang, J.
    Berry, M. F.
    Lui, N. S.
    Liou, D. Z.
    Trope, W. L.
    Backhus, L. M.
    Shrager, J. B.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S484 - S485
  • [43] Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma
    Marks, Jenifer L.
    Broderick, Stephen
    Zhou, Qin
    Chitale, Dhananjay
    Li, Allan R.
    Zakowski, Maureen F.
    Kris, Mark G.
    Rusch, Valerie W.
    Azzoli, Christopher G.
    Seshan, Venkatraman E.
    Ladanyi, Marc
    Pao, William
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (02) : 111 - 116
  • [44] EGFR and KRAS mutations are molecular predictors of survival in resected lung adenocarcinoma
    Marks, Jenifer L.
    Broderick, Stephen
    Seshan, Venkatraman E.
    Zakowski, Maureen F.
    Li, Allan
    Wilson, Richard
    Kris, Mark G.
    Ladanyi, Mark
    Rusch, Valerie W.
    Pao, William
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S480 - S481
  • [45] Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma
    Riely, Gregory J.
    Kris, Mark G.
    Rosenbaum, Daniel
    Marks, Jenifer
    Li, Allan
    Chitale, Dhananjay A.
    Nafa, Khedoudja
    Riedel, Elyn R.
    Su, Meier H.
    Pao, William
    Miller, Vincent A.
    Ladanyi, Marc
    CLINICAL CANCER RESEARCH, 2008, 14 (18) : 5731 - 5734
  • [46] Prognostic implications of EGFR and KRAS gene mutations in resected lung adenocarcinoma
    Janjigian, Yelena Y.
    Kris, Mark G.
    Pao, William
    Marks, Jenifer L.
    Zheng, Junting
    Shen, Ronglai
    Dycoco, Joseph P.
    Park, Bernard J.
    Riely, Grey J.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S333 - S333
  • [47] Clinical Outcomes of Patients with Lung Adenocarcinoma Harboring Concomitant Driver Mutations in a Brazilian Cancer Center
    Costa, M.
    Santos, M.
    Teixeira, C.
    Tabacoff, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S986 - S986
  • [48] Prognostic implications of smoking in patients with advanced lung adenocarcinoma excluding positive mutations
    Kato, Tomohiro
    Nakahara, Yasuharu
    Hirano, Katsuya
    Kominami, Ryota
    Onishika, Yasutaka
    Fukuda, Yasushi
    Kagami, Ryogo
    Katsuda, Runko
    Hanaoka, Kenji
    Yokoi, Yoko
    Miyake, Kouhei
    Mizumori, Yasuyuki
    Tsukamoto, Hiroaki
    Sasaki, Shin
    Kawamura, Tetsuji
    Mochizuki, Yoshiro
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [49] KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy
    Ghimessy, Aron Kristof
    Gellert, Aron
    Schlegl, Erzsebet
    Hegedus, Balazs
    Raso, Erzsebet
    Barbai, Tamas
    Timar, Jozsef
    Ostoros, Gyula
    Megyesfalvi, Zsolt
    Gieszer, Balazs
    Moldvay, Judit
    Renyi-Vamos, Ferenc
    Lohinai, Zoltan
    Hoda, Mir Alireza
    Klikovits, Thomas
    Klepetko, Walter
    Laszlo, Viktoria
    Dome, Balazs
    CANCERS, 2019, 11 (10)
  • [50] Immunotherapy Outcomes in KRAS Mutated vs KRAS Wild-Type Advanced Lung Adenocarcinoma
    Collons, D.
    Nguyen, R.
    Khan, M.
    Schwartz, C.
    Pasquinelli, M.
    Feldman, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S409 - S410
12345